TRDA Stock Analysis: Buy, Sell, or Hold?
TRDA - Entrada Therapeutics, Inc. Common Stock
$6.60
-0.32 (-4.62%)
▼
5d:
-12.35%
30d:
+10.55%
90d:
-51.11%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 05, 2026
21d
Get Alerted When TRDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TRDA is down 12.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TRDA is down 12.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TRDA is currently trading at $6.60, which is considered slightly low relative to its 30-day fair value range of $6.47 to $7.53.
Technical Outlook: Technically, TRDA is in a strong downtrend. The price is currently testing key support at $6.51. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.75 (+184.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TRDA is in a strong downtrend. The price is currently testing key support at $6.51. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.75 (+184.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$6.47 -
$7.53
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 184.1% below Wall St target ($18.75)
- WARNING: Recommendation downgraded due to -12.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$6.47 -
$7.53
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$6.51
Resistance Level
$8.10
Current Trend
Strong Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.03
Wall Street Target
$18.75
(+184.1%)
Revenue Growth (YoY)
-95.7%
Share & Embed Analysis
Last updated: July 14, 2026 3:07 AM ET
Data refreshes hourly during market hours. Next update: 4:07 AM
Data refreshes hourly during market hours. Next update: 4:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Kory James Wentworth
SELL
2500 shares
2026-04-01
Kory James Wentworth
SELL
11388 shares
2026-03-10
Nathan J Dowden
SELL
11894 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 60 HOLD |